Clinical trial
Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute…
NCT00216671 · Janssen Pharmaceutica N.V., Belgium, Industry · Completed
Key facts
| NCT number | NCT00216671 |
|---|---|
| Title | Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode |
| Official title | Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode |
| Lead sponsor | Janssen Pharmaceutica N.V., Belgium, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | early initiation of treatment with Risperdal Consta, routine initiation of treatment with Risperdal Consta |
| Enrollment | 220 |
| Start date | Nov 1, 2005 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 22, 2005 |
| Last update posted | Jul 19, 2013 |
| Countries | Denmark, Finland, France, Greece, Israel, Norway, Slovenia, Sweden, Switzerland, United Kingdom |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: